☰

Judith Michels - Publications

Affiliations: 
University Paris 11 
Area:
DNA repair, PARP, Cisplatin, Synthetic lethality, Non small cell lung cancer, HR, BRCA, Cisplatin resistance, BER
Tree Info Similar researchers PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Juncheng P, Joseph A, Lafarge A, Martins I, Obrist F, Pol J, Saavedra E, Li S, Sauvat A, Cerrato G, Lévesque S, Leduc M, Kepp O, Durand S, Aprahamian F, ... ... Michels J, et al. Cancer cell-autonomous overactivation of PARP1 compromises immunosurveillance in non-small cell lung cancer. Journal For Immunotherapy of Cancer. 10. PMID 35772809 DOI: 10.1136/jitc-2021-004280  0.574
2022 Tayoun T, Faugeroux V, Oulhen M, Déas O, Michels J, Brulle-Soumare L, Cairo S, Scoazec JY, Marty V, Aberlenc A, Planchard D, Remon J, Ponce S, Besse B, Kannouche PL, et al. Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explants. Jci Insight. 7. PMID 35511434 DOI: 10.1172/jci.insight.155804  0.437
2021 Joseph A, Pan J, Michels J, Kroemer G, Castedo M. Pyridoxal kinase and poly(ADP-ribose) affect the immune microenvironment of locally advanced cancers. Oncoimmunology. 10: 1950954. PMID 34290910 DOI: 10.1080/2162402X.2021.1950954  0.461
2021 Joseph A, Juncheng P, Mondini M, Labaied N, Loi M, Adam J, Lafarge A, Astesana V, Obrist F, Klein C, Bloy N, Stoll G, Signolle N, Genestie C, Damotte D, ... ... Michels J, et al. Metabolic features of cancer cells impact immunosurveillance. Journal For Immunotherapy of Cancer. 9. PMID 34162714 DOI: 10.1136/jitc-2021-002362  0.513
2020 Leary A, Genestie C, Blanc-Durand F, Gouy S, Dunant A, Maulard A, Drusch F, Cheaib B, Michels J, Bentivegna E, LeFormal A, Mesnage S, Morice P, Pautier P, Khairallah AS. Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer. Cancer Immunology, Immunotherapy : Cii. PMID 32852603 DOI: 10.1007/S00262-020-02670-0  0.408
2020 Joseph A, Castedo-Delrieu M, Bloy N, Labaied N, Mondini M, Loi M, Klein C, Genestie C, Pautier P, Morice P, Gouy S, Deutsch E, Chargary C, Kroemer G, Michels J. Prognostic value of dendritic cells in locally advanced cervical cancer patients. Journal of Clinical Oncology. 38: e18016-e18016. DOI: 10.1200/Jco.2020.38.15_Suppl.E18016  0.467
2019 Stoll G, Kremer M, Bloy N, Joseph A, Castedo M, Meurice G, Klein C, Galluzzi L, Michels J, Kroemer G. Metabolic enzymes expressed by cancer cells impact the immune infiltrate. Oncoimmunology. 8: e1571389. PMID 31069148 DOI: 10.1080/2162402X.2019.1571389  0.662
2019 Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, et al. T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30924846 DOI: 10.1093/Annonc/Mdz112  0.448
2019 Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, Michot JM, Marabelle A, Lambotte O, Amoura Z, Soria JC, et al. Renal toxicities associated with pembrolizumab. Clinical Kidney Journal. 12: 81-88. PMID 30746132 DOI: 10.1093/Ckj/Sfy100  0.31
2018 Obrist F, Michels J, Durand S, Chery A, Pol J, Levesque S, Joseph A, Astesana V, Pietrocola F, Wu GS, Castedo M, Kroemer G. Metabolic vulnerability of cisplatin-resistant cancers. The Embo Journal. PMID 29875130 DOI: 10.15252/Embj.201798597  0.73
2018 Edith B, Leary A, Pautier P, Santana E, Lacroix L, Cabaret O, Guillaud-Bataille M, Michels J, Auguste A, Genestie C, Rouleau E. Combined tumor-based BRCA/TP53 mutation testing in ovarian cancer Annals of Oncology. 29: viii43. DOI: 10.1093/Annonc/Mdy269.133  0.34
2017 Gizzi M, Oberic L, Massard C, Poterie A, Le Teuff G, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K. Corrigendum to "Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours" [Eur J Cancer 69 (2016) 151-157]. European Journal of Cancer (Oxford, England : 1990). PMID 28283351 DOI: 10.1016/J.Ejca.2017.02.014  0.437
2017 Mesnage SJL, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, Gouy S, Morice P, Bentivegna E, Lhomme C, Pautier P, Michels J, Le Formal A, Cheaib B, Adam J, et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 651-657. PMID 27864219 DOI: 10.1093/Annonc/Mdw625  0.303
2017 Leary A, Genestie C, Boursin Y, Adam J, Leformal-Ensarguex A, Gouy S, Morice P, Bentivegna E, Pautier P, Michels J, Job B, Deloger M, Mesnage S, Auguste A. Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer Annals of Oncology. 28: v337-v338. DOI: 10.1093/Annonc/Mdx372.019  0.364
2017 Khairallah A, Auguste A, Leary A, Genestie C, Pautier P, Michels J, Morice P, Bentivegna E, Maulard A, Drusch F, Mesnage S, Gouy S. An increased ratio of cytotoxic to suppressive T cells after neoadjuvant chemotherapy (NACT) is prognostic in advanced ovarian cancer Annals of Oncology. 28: v334. DOI: 10.1093/Annonc/Mdx372.009  0.431
2016 Gizzi M, Oberic L, Massard C, Poterie A, Gwenael LT, Loriot Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. European Journal of Cancer (Oxford, England : 1990). 69: 151-157. PMID 27821318 DOI: 10.1016/J.Ejca.2016.10.003  0.334
2016 Stoll G, Iribarren K, Michels J, Leary A, Zitvogel L, Cremer I, Kroemer G. Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. Oncoimmunology. 5: e1177692. PMID 27622029 DOI: 10.1080/2162402X.2016.1177692  0.561
2016 Marabelle A, Routy B, Michels J, Kroemer G, Zitvogel L. Prime time for immune-checkpoint targeted therapy at ASCO 2015. Oncoimmunology. 5: e1068494. PMID 27141332 DOI: 10.1080/2162402X.2015.1068494  0.421
2016 Faugeroux V, Deas O, Michels J, Judde JG, Cairo S, Vielh P, Marty V, Billiot F, Ngocamus M, Besse B, Kannouche P, Farace F. Abstract 2256: Establishment and characterization of circulating tumor cell-derived xenografts in non-small cell lung cancer Cancer Research. 76: 2256-2256. DOI: 10.1158/1538-7445.Am2016-2256  0.532
2015 Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 26: 2470-7. PMID 26387143 DOI: 10.1093/Annonc/Mdv393  0.652
2014 Michels J, Obrist F, Castedo M, Vitale I, Kroemer G. PARP and other prospective targets for poisoning cancer cell metabolism. Biochemical Pharmacology. 92: 164-71. PMID 25199458 DOI: 10.1016/J.Bcp.2014.08.026  0.559
2014 Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G. MCL-1 dependency of cisplatin-resistant cancer cells. Biochemical Pharmacology. 92: 55-61. PMID 25107702 DOI: 10.1016/J.Bcp.2014.07.029  0.792
2014 Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death & Disease. 5: e1257. PMID 24874729 DOI: 10.1038/Cddis.2013.428  0.694
2014 Lissa D, Senovilla L, Rello-Varona S, Vitale I, Michaud M, Pietrocola F, Boilève A, Obrist F, Bordenave C, Garcia P, Michels J, Jemaà M, Kepp O, Castedo M, Kroemer G. Resveratrol and aspirin eliminate tetraploid cells for anticancer chemoprevention. Proceedings of the National Academy of Sciences of the United States of America. 111: 3020-5. PMID 24516128 DOI: 10.1073/Pnas.1318440111  0.758
2014 Michels J, Goubar A, Adam J, Galluzzi L, Olaussen KA, Robin A, Girard P, Kremer I, Castedo M, Soria J, Kroemer G. Abstract 4691: Overactivation of poly (ADP-ribose) polymerase (PARP) in localised non-small cell lung cancer (NSCLC) predicts dismal prognosis Cancer Research. 74: 4691-4691. DOI: 10.1158/1538-7445.Am2014-4691  0.652
2013 Michels J, Vitale I, Galluzzi L, Adam J, Olaussen KA, Kepp O, Senovilla L, Talhaoui I, Guegan J, Enot DP, Talbot M, Robin A, Girard P, Oréar C, Lissa D, et al. Cisplatin resistance associated with PARP hyperactivation. Cancer Research. 73: 2271-80. PMID 23554447 DOI: 10.1158/0008-5472.Can-12-3000  0.778
2013 Michels J, Kepp O, Senovilla L, Lissa D, Castedo M, Kroemer G, Galluzzi L. Functions of BCL-X L at the Interface between Cell Death and Metabolism. International Journal of Cell Biology. 2013: 705294. PMID 23533418 DOI: 10.1155/2013/705294  0.755
2013 Michels J, Vitale I, Senovilla L, Enot DP, Garcia P, Lissa D, Olaussen KA, Brenner C, Soria JC, Castedo M, Kroemer G. Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer. Cell Cycle (Georgetown, Tex.). 12: 877-83. PMID 23428903 DOI: 10.4161/Cc.24034  0.788
2013 Galluzzi L, Goubar A, Olaussen KA, Vitale I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire P, Fouret P, Behrens C, Wistuba II, Soria JC, Kroemer G. Prognostic value of LIPC in non-small cell lung carcinoma. Cell Cycle (Georgetown, Tex.). 12: 647-54. PMID 23343765 DOI: 10.4161/Cc.23517  0.657
2013 Galluzzi L, Vacchelli E, Michels J, Garcia P, Kepp O, Senovilla L, Vitale I, Kroemer G. Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. Oncogene. 32: 4995-5004. PMID 23334322 DOI: 10.1038/Onc.2012.623  0.75
2013 Galluzzi L, Marsili S, Vitale I, Senovilla L, Michels J, Garcia P, Vacchelli E, Chatelut E, Castedo M, Kroemer G. Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. Cell Cycle (Georgetown, Tex.). 12: 417-21. PMID 23287530 DOI: 10.4161/Cc.23275  0.777
2012 Galluzzi L, Vitale I, Senovilla L, Olaussen KA, Pinna G, Eisenberg T, Goubar A, Martins I, Michels J, Kratassiouk G, Carmona-Gutierrez D, Scoazec M, Vacchelli E, Schlemmer F, Kepp O, et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Reports. 2: 257-69. PMID 22854025 DOI: 10.1016/J.Celrep.2012.06.017  0.668
2012 Michels J, Vitale I, Galluzzi L, Kepp O, Senovilla L, Olaussen KA, Soria J, Castedo M, Kroemer G. Abstract 3115: PARP overactivation predicts the susceptibility of human cancer cells to apoptosis induction by PARP inhibitors Cancer Research. 72: 3115-3115. DOI: 10.1158/1538-7445.Am2012-3115  0.704
2011 Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 31: 1869-83. PMID 21892204 DOI: 10.1038/Onc.2011.384  0.633
2010 Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Critical Reviews in Oncology/Hematology. 74: 27-39. PMID 19781957 DOI: 10.1016/J.Critrevonc.2009.08.005  0.334
2008 McGuire WP, Hirte HW, Matulonis UA, Penson RT, Husain A, Hoskins PJ, Michels J, Michelson G, Chiang A, Aghajanian CA. A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5582. PMID 27950396 DOI: 10.1200/jco.2008.26.15_suppl.5582  0.4
Show low-probability matches.